ADIL - Biotech News Driving These Companies
HENDERSON, NV / ACCESSWIRE / December 26, 2018 / The news isn't all gloom and doom, the biotech companies highlighted below have all released positive news recently.
We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), Auris Medical Holding AG (EARS), Acorda Therapeutics, Inc. (NASDAQ: ACOR), and ArQule, Inc. (NASDAQ: ARQL).
According to the FDA, more than 72,000 people died from drug overdoses in 2017, including overdoses due to illicit drugs and prescription opioids.Biotech and CBD companies are both working on different solutions to this dire issue.One of which has just announced something that makes us even more intrigued than we already were. Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $8.167M, Share Price: $0.0207), a commercial-stage developer of non-invasive wearable Electroceuticalsâ„¢ Therapies, has developed a therapy that has shown tosignificantly reduce postoperative pain without the kinds of side effects of many other opioid alternatives.Their non-invasive easy to use ORTHOHALOâ„¢ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.
The announcement that peaked our interest is that ENDV has formed a partnership with US Authentic Trading Company (USAT) to act as the exclusive partner to assist with facilitating a relationship between the Company and China.China has been dealing with opioids since the 1600s, all the way back to the Opium wars.This market added to the already robust US market makes ENDV one of the most enticing opioid alternative plays on the market.
Finally, the company just announced the allowance for the patent application entitled Devices And Method For Treatment Of Degenerative Joint Diseases With Electromagnetic Fields by the U.S. Patent and Trademark Office. Endonovo will be including this technology under its WOUNDPULSEâ„¢ brand.
Adial Pharmaceuticals, Inc. (ADIL) (Market Cap: $32.453M, Share Price: $4.95) a company developing medicines for addiction, just announced that the holder of the sole remaining, outstanding convertible note has fully converted the balance of the note into common shares of the Company. As previously reported, the convertible note had a face value of $325,000 and was convertible into 162,500 shares of common stock.
Auris Medical Holding AG (EARS) (Market Cap: $13.167M, Share Price: $0.385) a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care announced a strategic expansion for its intranasal betahistine development program. In two related transactions, the company has acquired an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS) and signed a binding letter of intent to in-license exclusive rights to two US Patents relating to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD), respectively.
Acorda Therapeutics, Inc. (ACOR) (Market Cap: $654.878M, Share Price: $13.77) has been on a run since the U.S. Food and Drug Administration approved its therapy for Parkinson's disease. The drug, which will be sold under the name Inbrija, is an inhaled version of levodopa, an existing therapy that treats the effects of the neurodegenerative disorder. Acorda declined to say how it plans to price the product, and an outside spokesman said Acorda was still in conversations with insurers and the price would be made public next year.
ArQule, Inc. (ARQL) (Market Cap: $263.765M, Share Price: $2.42) was added to the NASDAQ Biotechnology Index (Nasdaq:NBI), Monday, December 24, 2018.
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting").Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve-month agreement, and can be canceled at any time by the issuer ENDV.All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of.Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article.Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice.This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein.Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: Regal Consulting, LLC